Vedolizumab clearance and exposure
A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.
- Therapeutic
- Vedolizumab
- Target
- Not reported
- Disease
- Inflammatory bowel disease
Biological model
A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.
Intervention
Vedolizumab
Biological focus
PopPK, Exposure-response
Context
Inflammatory bowel disease
Model details
A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.
Modeled states
- AUC central mg day Lmg*day/L
Modeled dynamic state for auc central mg day l.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
Key readouts
- Central vedolizumab concentrationunknown
Model-derived readout for central vedolizumab concentration.
- Cumulative vedolizumab exposureunknown
Model-derived readout for cumulative vedolizumab exposure.
- Effective clearanceunknown
Model-derived readout for effective clearance.
- AUC central mg day Lmg*day/L
Model-derived readout for auc central mg day l.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
0-2-6w + 10w + every 4 weeks, prior anti-TNF no
How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure?
CL L day
Model parameter controlling cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World PharmacokineticsPharmaceutics
